Disease progression and sphingolipids and neurofilament-light chain in early idiopathic Parkinson's disease

Blas Couto; Mario Sousa; Paulina Gonzalez-Latapi; Eric McArthur; Anthony Lang; Alice Chen-Plotkin; Connie Marras

doi:10.1017/cjn.2023.281

Disease progression and sphingolipids and neurofilament-light chain in early idiopathic Parkinson's disease

Blas Couto, Mario Sousa, Paulina Gonzalez-Latapi, Eric McArthur, Anthony Lang, Alice Chen-Plotkin, Connie Marras^*

^*Corresponding author for this work

Neurology

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

Parkinson's Disease(PD) lacks a biomarker for disease progression.

Original language	English (US)
Journal	Canadian Journal of Neurological Sciences
DOIs	https://doi.org/10.1017/cjn.2023.281
State	Accepted/In press - 2023

ASJC Scopus subject areas

Neurology
Clinical Neurology

Access to Document

10.1017/cjn.2023.281

Cite this

@article{67c61f4d8a194aee81e28e14bfd64fb3,

title = "Disease progression and sphingolipids and neurofilament-light chain in early idiopathic Parkinson's disease",

abstract = "Parkinson's Disease(PD) lacks a biomarker for disease progression.",

author = "Blas Couto and Mario Sousa and Paulina Gonzalez-Latapi and Eric McArthur and Anthony Lang and Alice Chen-Plotkin and Connie Marras",

note = "Publisher Copyright: {\textcopyright}), Montreal cognitive assesment(MoCA) or global composite outcome(GCO)-score. In 191 PD-patients, biomarkers were not associated with DaTscan or MoCA change over 2.1-years. Higher baseline GlcCer/SM-ratio and serum-NfL non-significantly associated with increase in GCO-score. Results do not support a role for CSF- sphingolipid/serum-NfL to predict cognitive and DaTscan progression in early-PD. Potential prediction of global clinical change warrants further study.",

year = "2023",

doi = "10.1017/cjn.2023.281",

language = "English (US)",

journal = "Canadian Journal of Neurological Sciences",

issn = "0317-1671",

publisher = "Canadian Journal of Neurological Sciences",

}

TY - JOUR

T1 - Disease progression and sphingolipids and neurofilament-light chain in early idiopathic Parkinson's disease

AU - Couto, Blas

AU - Sousa, Mario

AU - Gonzalez-Latapi, Paulina

AU - McArthur, Eric

AU - Lang, Anthony

AU - Chen-Plotkin, Alice

AU - Marras, Connie

N1 - Publisher Copyright: ©), Montreal cognitive assesment(MoCA) or global composite outcome(GCO)-score. In 191 PD-patients, biomarkers were not associated with DaTscan or MoCA change over 2.1-years. Higher baseline GlcCer/SM-ratio and serum-NfL non-significantly associated with increase in GCO-score. Results do not support a role for CSF- sphingolipid/serum-NfL to predict cognitive and DaTscan progression in early-PD. Potential prediction of global clinical change warrants further study.

PY - 2023

Y1 - 2023

N2 - Parkinson's Disease(PD) lacks a biomarker for disease progression.

AB - Parkinson's Disease(PD) lacks a biomarker for disease progression.

UR - http://www.scopus.com/inward/record.url?scp=85170280812&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85170280812&partnerID=8YFLogxK

U2 - 10.1017/cjn.2023.281

DO - 10.1017/cjn.2023.281

M3 - Article

C2 - 37641969

AN - SCOPUS:85170280812

SN - 0317-1671

JO - Canadian Journal of Neurological Sciences

JF - Canadian Journal of Neurological Sciences

ER -

Disease progression and sphingolipids and neurofilament-light chain in early idiopathic Parkinson's disease

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this